Trump Reclassifies Medical Cannabis to Schedule III Drug Status
Federal rescheduling moves state-licensed medical marijuana from Schedule I to same category as prescription painkillers, marking historic shift in cannabis policy.
The Trump administration has officially moved state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, placing cannabis in the same federal category as prescription painkillers like codeine and anabolic steroids. This reclassification represents the most significant federal cannabis policy shift in decades, removing marijuana from the same category as heroin and LSD where it has resided since 1970.
The rescheduling creates immediate tax advantages for state-licensed cannabis operators, who can now deduct standard business expenses under federal tax code. Previously, Section 280E prohibited cannabis companies from claiming deductions beyond cost of goods sold, creating effective tax rates exceeding 70% for many operators. Multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve stand to benefit most from the tax relief, potentially improving margins by 15-25 percentage points.
Schedule III status maintains federal restrictions on interstate commerce and banking services, limiting the immediate operational impact for cannabis companies. The rescheduling does not legalize recreational marijuana at the federal level or resolve the conflict between state and federal law that has created a complex patchwork of regulations across different jurisdictions. Cannabis businesses still cannot access traditional banking services or list on major U.S. stock exchanges.
The policy change validates the medical efficacy arguments that cannabis advocates have made for years, potentially accelerating research into therapeutic applications. Pharmaceutical companies may increase investment in cannabis-derived medications, while existing cannabis operators gain legitimacy with institutional investors who previously avoided the sector due to federal scheduling concerns.
Cannabis stocks have rallied on rescheduling speculation throughout 2024, with the AdvisorShares Pure US Cannabis ETF gaining over 40% year-to-date. The formal rescheduling removes a major regulatory overhang that has suppressed valuations across the sector, though companies still face challenges from state-by-state regulations and limited access to capital markets. The move positions the U.S. cannabis industry for accelerated growth as federal and state policies continue converging toward broader acceptance.